NCT05283616View on ClinicalTrials.gov

Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

May 15, 2017

Primary Completion Date

October 10, 2019

Study Completion Date

October 15, 2021

Conditions
Neutropenia
Interventions
DRUG

Pegfilgrastim

Pegfilgrastim 3mg per chemotherapy cycle

Trial Locations (1)

100021

Department of Medical Oncology, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT05283616 - Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer | Biotech Hunter | Biotech Hunter